生物化学与分子生物学硕士专业
Master’s Program in Biochemistry and Molecular
Biology
导师介绍 Supervisor Profiles
李冠武 Guanwu Li
邮箱及联系电话：gwli@stu.edu.cn, 86-13612396599
Email & Contact Number：gwli@stu.edu.cn, 86-13612396599
研究方向 ：细胞自噬与肿瘤
Research Field：Autophagy and Tumor
导师简介 Biography：
李冠武，男， 1999 年毕业于中国科技大学生命科学学院，获生化与分子生物学 专业理学博士学位。汕头大学医学院肿瘤分子生物开放实验室负责人， 生化与分 子生物学专业教授，具有硕士生导师、博士后合作导师资格。其课题组对于白藜 芦醇诱导肿瘤细胞凋亡、自噬有多年的研究基础， 主要研究方向为细胞自噬和凋 亡的相互联系及转换机制。已有 8 名研究生完成白藜芦醇对食管癌细胞、白血病 细胞和肺腺癌细胞自噬的研究。目前主要围绕肿瘤药物诱导细胞自噬及相关机制 的研究，研究发现细胞自噬的作用并不仅仅限于传统意义的细胞保护作用，细胞 自噬也是细胞死亡的机制之一，甚至可能是某些细胞凋亡的必经之路。作为项目 负责人，先后主持各种科研项目，包括国家自然科学基金面上项目、教育部霍英 东基金、广东省自然科学基金面上项目以及广东省科学技术厅项目等。作为导师， 指导硕士研究生累计 30 余名，在读研究生 5 名；指导本科大学生从事创新科学 研究 15 人（获得大创项目三项，其中省级两项目、国家级一项）； 近五年来，在 J Cellular Physiology 、Cancer Letter、Biochemical Pharmacology 等国际学术期刊 上发表研究论文。
最近他的课题组研究发现 LC3 通过线粒体自噬及 Pink1/Parkin 通路，参与细胞自 噬和凋亡之间转换的调控。
Guanwu Li, graduated from The School of Life Sciences, University of Science and Technology of China in 1999 with a doctorate degree in Biochemistry and Molecular Biology. Now he is the Director of the Open Laboratory of Molecular Oncology, Shantou University Medical College, Professor in Biochemistry and Molecular Biology, master supervisor and postdoctoral co-supervisor. The research group has
many years of research foundation on resveratrol-induced apoptosis and autophagy in tumor, and the interaction and transformation mechanism of autophagy and apoptosis.
At present, the research mainly focuses on the tumor drug-induced autophagy and related mechanisms. It has been found that autophagy is not only limited to the traditional protective effect of cells, but also one of the mechanisms of cell death, and may even be the dependent way of apoptosis in some cells.
Recently, his research group found that LC3 is involved in the regulation of the transition between autophagy and apoptosis through mitochondrial autophagy and Pink1/Parkin pathway.
代表性研究论文(共同第一作者或通讯作者)： Publication list：
[1] Li G, He S, Chang L, Lu H, Zhang H, Zhang H, Chiu J. GADD45α and annexin A1 are involved in the apoptosis of HL-60 induced by resveratrol. Phytomedicine. 2011 Jun 15;18(8-9):704-9
[2] Li G, Lee LS#, Li M, Tsao SW, Chiu JF. Molecular Changes during Arsenic-Induced Cell Transformation. J Cell Physiol. 2011 Dec;226(12):3225-32.
[3] Jiao RQ, Li G, Chiu JF. Comparative proteomic analysis of differentiation of mouse F9 embryonic carcinoma cells induced by retinoic acid. J Cell Biochem. 2012 Jun;113(6):1811-9.
[4] Tang Q, Li G#, Wei X, Zhang J, Chiu JF, Hasenmayer D, Zhang D, Zhang H. Resveratrol-induced apoptosis is enhanced by inhibition of autophagy in esophageal squamous cell carcinoma. Cancer Lett. 2013 Aug 19;336(2):325-37.
[5] Jun Zhang, JenFu Chiu, Hongwei Zhang, Tingting Qi, Qishan Tang, Ke Ma, Hong Lu, Guanwu Li*, Autophagic cell death induced by resveratrol depends on the Ca2+/AMPK/mTOR pathway in A549 cells. Biochemical Pharmacology. 2013 July 86( 2), 317–328.
[6] Jun Zhang, Ke Ma, Tingting Qi, Xiaoning Wei, Qing Zhang, Guanwu Li* and Jen-Fu Chiu*. P62 regulates resveratrol-mediated Fas/Cav-1 complex formation and transition from autophagy to apoptosis. Oncotarget. 2015 Jan 20;6(2):789-801
[7] Yingying Fan, Jen-Fu Chiu, Jing Liu, Yan Deng, Cheng Xu, Jun Zhang, and Guanwu Li. Resveratrol induces autophagy-dependent apoptosis in HL-60 cells. BMC Cancer, Volume 18, Issue 1, 22 May 2018,581
[8] Ningyu Huang, Xiaojuan Pei, Wenbo Lin, Jen-Fu Chiu, Tao Tao, and Guanwu Li. DNA methylation of a non-CpG island promoter represses NQO1 expression in rat arsenic-transformed lung epithelial cells. Acta Biochim Biophys Sin，2018, 50(8), 733–739
[9] Jiahua Zheng, ShaochaiWei,TingtingXiao, Guanwu Li*. LC3B/p62-mediated mitophagy protects A549 cells from resveratrol-induced apoptosis. Life Sciences,Volume 271, 15 April 2021, 119139
东庚 Geng Dong
邮箱及联系电话:gdong@stu.edu.cn
Email & Contact Number：gdong@stu.edu.cn
研究方向: 计算生物化学
Research Field: Computational Biochemistry
导师简介 Biography：
汕头大学医学院特聘教授，博导。2018 年 7 月获瑞典隆德大学（Lund University） 理论化学专业博士学位。2018 年 9 月入职汕头大学医学院，研究领域是计算生 物化学。研究方向是通过理论计算模拟等手段/信息技术平台研究：1）肿瘤中生 物酶酶促反应机理，揭示其分子作用机制及其结构-功能关系；2）与肿瘤相关的 蛋白-蛋白或药物-蛋白之间相互作用， 以及分子对接后对蛋白结构的影响，为药 物的临床转化研究提供理论依据。作为研究生导师，指导硕士研究生 5 人，博 士研究生 3 人。在《J. Am. Chem. Soc.》 、《Chem. Sci.》和《ACS Catal.》等国 际主流学术杂志发表研究论文 27 篇。参与著书一部。个人网页：
https://www.x-mol.com/groups/Dong
Prof. Dr. Geng Dong received his PhD in 2018 working with Prof. Ulf Ryde. Then, he joined Shantou University Medical College for computational biochemistry as group leader. Dong has published 27 scientific articles in journals of chemistry and biochemistry. His work focuses on the reaction mechanism of enzymes, ligand binding, protein-protein interaction, as well as drug design by using theoretical methods, e.g., QM cluster calculation, QM/MM calculation, MD simulation etc.
More information can be found on https://www.x-mol.com/groups/Dong.
卢玺峰 Xifeng Lu
邮箱及联系电话：xifeng.lu@outlook.com, 86-13168778436
Email & Contact Number：xifeng.lu@outlook.com, 86-13168778436
研究方向: V-ATPase 与代谢调控
Research Field：The role of Vacuolar H+-ATPase in metabolic regulation
导师简介 Biography：
汕头大学医学院/汕头大学医学院第一附属医院特聘教授。2014 年毕业于荷兰鹿 特丹伊拉斯姆斯，获博士学位。2014 年 11 月至 2021 年 08 月在深圳大学医学部 工作，历任讲师、副教授。2021 年 09 月至 2022 年 08 月在深圳技术大学药学院 工作，任药理学教授。2022 年 09 月起在汕头大学医学院工作。主要研究方向为
胆固醇代谢调控分子机制、V-ATPase 在代谢调控中的作用、以及代谢紊乱性疾 病防治药物的开发。主持国家级项目 3 项，其它省、市、厅级等各类项目 6 项， 总经费金额达 700 余万元人民币。在 Circulation Research、Nature Communications、 Organic Letters、Biomaterials、Pharmacological Research、Frontiers in Cardiovascular Medicine 等一流学术期刊上发表论文 30 余篇，申请并获得国家发明专利授权 1 项。指导硕士研究生 7 名，博士研究生 7 名。
Xifeng Lu is a distinguished Professor jointly appointed by Shantou University School of Medicine and the First Affiliated Hospital of Shantou University School of Medicine. Xifeng Lu was awarded a PhD degree in pharmacology by Erasmus University Rotterdam in Jan 2014. After his PhD, Dr. Lu worked as postdoc fellow at Erasmus Medical Center (EMC, Rotterdam) and Academic Medical Center (AMC, Amsterdam) until he joined Shenzhen University. Dr. Lu served as assistant professor and associate professor at Shenzhen University Health Science Center during Nov 2014 and Aug 2021. From Sep 2021, Dr. Lu served as Professor in Pharmacology at Shenzhen Technology University until he joined Shantou University School of Medicine in Sep 2022. The research of Xifeng focused on elucidating the role of Vacuolar H+-ATPase in metabolic control, identification of novel regulators in cholesterol metabolism, and developing drugs or other therapeutic ways to treat metabolic diseases. Xifeng received 3 grants from NSFC and 6 others grants from Guangdong Province or Shenzhen Municipal, which amounted to more than 7 million RMB. Xifeng has authored more than 30 articles in top-class journals such as Circulation Research, Nature Communications, Organic Letters, Biomaterials, Pharmacological Research, and Frontiers in Cardiovascular Medicine. Till now, Xifeng has supervised/co-supervised 7 master students and 7 PhD students.
沈文君 Wenjun Shen
邮箱及联系电话：wjshen@stu.edu.cn, 86-13676120002
Email & Contact Number：wjshen@stu.edu.cn, 86-13676120002
研究方向: 癌症基因组学、生物信息学、模式识别
Research Field：Cancer genomics，Bioinformatics，Pattern recognition
导师简介 Biography：
沈文君，博士毕业于香港城市大学计算机科学系；斯坦福大学访问学者。现为汕 头大学医学院生物信息教研室，副教授、硕士生导师。主要研究方向包括癌症基 因组学、生物信息学和模式识别，在 Foundations of Computational Mathematics， Journal of Experimental & Clinical Cancer Research, Genome biology, Cell Reports Methods, Cancers, Frontiers in Microbiology, Knowledge-Based Systems, Pattern Recognition 等重要期刊上发表论文 20 余篇。
Dr. Wenjun Shen earned her Ph.D. in Computer Science from the City University of
Hong Kong. From 2019 to 2020, she served as a visiting scholar at the School of Medicine, Stanford University. Currently, she is an associate professor in the Department of Bioinformatics at Shantou University Medical College. Her research focuses on cancer genomics, bioinformatics, and pattern recognition. She has authored over 20 papers in prestigious journals, including Foundations of Computational Mathematics, Journal of Experimental & Clinical Cancer Research, Genome Biology, Cell Reports Methods, Cancers, Frontiers in Microbiology, Knowledge-Based Systems, and Pattern Recognition.
林李锐 Lirui Lin
邮箱及联系电话：richardlin@stu.edu.cn;；+86-13570260327
Email & Contact Number：richardlin@stu.edu.cn; +86-13570260327
研究方向: 计算机辅助药物设计
Research Field：Computer-Aided Drug Design
Computer-aided drug design (CADD) is defined as a process that assists scientists in identifying and optimizing potential therapeutic compounds by utilizing computing power and biological knowledge, thereby reducing the time and cost of drug development.
导师简介 Biography：
林李锐汕头大学医学院，计算生物学专业，博士，讲师，硕士生导师。
基础医学部，生物信息学教研室/医学信息学研究中心，汕头市智能医学与药物 设计工程技术中心副主任（技术专利转化、企业对接）。汕头大学医学院学报青 年编委，全英教学老师，创新创业课程导师。主持广东省级自然科学基金面上项 目 1 项，广东省教育厅创新项目 1 项，在国际学术期刊发表研究论文 10 余篇， 指导多项大学生创新项目（2024 年度大创国家级立项。
Dr. Richard Lin holds a PhD in Computational Biology from Shantou University Medical College, where he serves as an instructor for master. He works for the Bioinformatics department and Medical Informatics Research Center of Shantou University medical college. He is deputy director of the Shantou Intelligent Medicine and Drug Design Engineering Technology Center, overseeing technology commercialization and industry partnerships. As a Young Editorial Board Member of the Journal of Shantou University Medical College, he is a English-based teaching specialist and mentor for innovation and entrepreneurship courses. His research portfolio includes: Guangdong Provincial Natural Science Foundation General Project, Guangdong Education Department Innovation Project, Mentorship for multiple undergraduate innovation projects (including a 2024 National-level Undergraduate Innovation Program).